NCT03693131View on ClinicalTrials.gov

Efficacy of MND-2119 in Participants With Hypertriglyceridemia

PHASE3CompletedINTERVENTIONAL
Enrollment

580

Participants

Timeline

Start Date

October 27, 2018

Primary Completion Date

June 15, 2019

Study Completion Date

June 29, 2019

Conditions
Hypertriglyceridemia
Interventions
DRUG

Icosapent (MND-2119)

Icosapent (MND-2119) capsules.

DRUG

Icosapent (EPADEL CAPSULES 300)

Icosapent (EPADEL CAPSULES 300) capsules.

Trial Locations (1)

Unknown

Mochida Investigational sites, Tokyo

Sponsors
All Listed Sponsors
lead

Mochida Pharmaceutical Company, Ltd.

INDUSTRY

NCT03693131 - Efficacy of MND-2119 in Participants With Hypertriglyceridemia | Biotech Hunter | Biotech Hunter